Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography

Area of Science:

• Pharmacokinetics
• Analytical Chemistry
• Medicinal Chemistry

Background:

• Discrepancies exist in methylphenidate (MPH) bioavailability data between older and newer analytical methods.
• Older gas chromatography (GC) methods reported significant l-MPH presence, while newer chiral liquid chromatography (LC) methods indicate d-MPH dominance.

Purpose of the Study:

• To explain the disparities in dl-MPH bioavailability data attributed to analytical methodology.
• To clarify the accurate enantiomeric composition of MPH in circulation.

Main Methods:

• Review and analysis of older chiral derivatization-gas chromatography (GC) methods.
• Comparison with recent chiral liquid chromatography (LC) findings.
• Hypothesizing the source of analytical error in older GC methods.

Main Results:

• Older GC methods using S-prolyl derivatizing agents were susceptible to R-prolyl impurities, causing co-elution with l-MPH and overestimation of l-MPH.
• Recent LC methods consistently demonstrate that approximately 99% of circulating MPH is the active d-enantiomer.
• This suggests older methods significantly underestimated d-MPH bioavailability.

Conclusions:

• The observed disparities in MPH bioavailability are likely due to imprecision in older chiral GC methods.
• Achiral analysis of plasma MPH is generally sufficient for d-MPH quantitation due to its high circulating percentage.
• Simultaneous monitoring of d-MPH and l-MPH may be necessary only in specific clinical or forensic scenarios involving altered metabolism or novel formulations.